Ultragenyx Pharmaceutical (RARE) Return on Capital Employed (2014 - 2026)
Ultragenyx Pharmaceutical (RARE) reported Return on Capital Employed of 51.52% for Q1 2026, down 549.0% year-over-year from 11.47% in Q1 2025, and up 5.9% quarter-over-quarter from 54.75% in Q4 2025.
Ultragenyx Pharmaceutical (RARE) Return on Capital Employed (2014 - 2026) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has 13 years of Return on Capital Employed data on file, last reported at 51.52% in Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 51.52%, down 549.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 51.52% (down 549.0% YoY), and the FY2025 annual result was 47.2%, down 71.0% from the prior year.
- Return on Capital Employed advanced to 51.52% in Q1 2026 per RARE's latest filing, from 54.75% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 32.02% in Q1 2022 and troughed at 60.99% in Q2 2023.
- A 5-year average of 49.52% and a median of 49.73% in 2025 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2023 and 2024: Return on Capital Employed slumped 2145 bps in 2023, then surged 1667 bps in 2024.
- A 5-year view of Return on Capital Employed shows it stood at 49.13% in 2022, then decreased by 7 bps to 52.48% in 2023, then grew by 13 bps to 45.55% in 2024, then dropped by 20 bps to 54.75% in 2025, then advanced by 6 bps to 51.52% in 2026.
- Business Quant data shows RARE's Return on Capital Employed at 51.52% in Q1 2026, 54.75% in Q4 2025, and 59.9% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Ultragenyx Pharmaceutical | 2.77 Bn | 2.36 Bn | 106.00 Mn | -51.52% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -51.52% |
| Dec 31, 2025 | -54.75% |
| Sep 30, 2025 | -59.90% |
| Jun 30, 2025 | -49.73% |
| Mar 31, 2025 | -46.03% |
| Dec 31, 2024 | -45.55% |
| Sep 30, 2024 | -41.41% |
| Jun 30, 2024 | -46.11% |
| Mar 31, 2024 | -50.30% |
| Dec 31, 2023 | -52.48% |
| Sep 30, 2023 | -58.07% |
| Jun 30, 2023 | -60.99% |
| Mar 31, 2023 | -53.47% |
| Dec 31, 2022 | -49.13% |
| Sep 30, 2022 | -48.77% |
| Jun 30, 2022 | -41.59% |
| Mar 31, 2022 | -32.02% |
| Dec 31, 2021 | -28.87% |
| Sep 30, 2021 | -27.54% |
| Jun 30, 2021 | -23.51% |